Roundup: Singaporean medical startup Oncoshot scores funding for India, Australia enlargement and extra briefs
Oncoshot receives funding to additional increase in India, Australia
Singaporean medical startup Oncoshot has scored an undisclosed funding by means of a pre-Sequence A funding spherical led by Biofurmis and Qure.ai investor MassMutual Ventures.
Based mostly on a press launch, the funding will help the corporate’s additional enlargement into India and Australia.
There are 4 hospital networks in India and a few networks of over 20 hospitals in Oceania which might be about to arrange their respective nationwide public-private medical trial ecosystems like Singapore’s Undertaking EISE. The latter makes use of Oncoshot’s medical trial matching platform to attach most cancers sufferers, healthcare professionals, and pharmaceutical and biotechnology firms.
It’s stated that medical trials worldwide lose round $35 billion annually because of inefficient processes in most cancers analysis and affected person recruitment.
Oncoshot has developed an answer to such points by enhancing the well being data of medical companions by means of AI and machine studying. Its federated information system securely hosts important and delicate affected person information inside hospital premises and gives full safety, entry and management of analyses and insights to hospital directors.
Well being data web site Happiest Well being goes stay in India
Indian IT service and consultancy agency Happiest Minds Applied sciences has launched a brand new on-line repository of well being and wellness data and knowledge.
Referred to as Happiest Well being, the web site goals to offer “in-depth, credible, and reliable” data on well being and wellness, in line with a press assertion.
It can educate its viewers with breakthroughs and developments in well being and wellness, sourced from new analysis and research from companion world institutes. The portal can even put a highlight on new instruments for early prognosis, in addition to person tales and feedback.
Furthermore, a panel of medical doctors and wellness specialists will contribute visitor essays and articles that provide distinctive views and attention-grabbing medical experiences.
“Via Happiest Well being, we wish to construct the significance of built-in drugs, present helpful data by means of specialists on early prognosis and evidence-based therapies and accomplish that with empathy and fervour,” stated Happiest Well being chairman Ashok Soota.
By subsequent yr, the web site will publish written and video content material in regional languages to cater to lower-tier cities in India. Happiest Well being can even launch a podcast, internet sequence, and audio content material quickly.
Medical trials in India affirm AI’s effectiveness in detecting referable glaucoma
Indian medical system maker Remidio Modern Options has reported optimistic outcomes from separate medical trials of its AI answer in detecting referable glaucoma.
Remidio affords an built-in screening answer for referable glaucoma, a stage whereby the illness can nonetheless be higher managed by means of therapy. It consists of a fundus on telephone, a retinal imaging system, and an AI algorithm for offline inferencing. The Medios Referable Glaucoma AI detects structural adjustments within the optic nerve head and surrounding retinal nerve fibre layer.
In keeping with a press assertion, the entire detection course of solely takes 15 seconds.
The corporate lately partnered with two native eye hospitals, Aravind Eye Hospital in Pondicherry and Narayana Nethralaya (NN) in Bangalore, to check its screening answer.
Within the medical trial at NN, the AI algorithm was discovered to achieve a excessive sensitivity of 93.5% and excessive specificity of 85.4% in detecting referable glaucoma whereas early outcomes from the medical trial at Aravind confirmed the algorithm to additionally obtain excessive sensitivity and specificity of 91.3% and 91.67%, respectively.
The corporate famous that whereas therapy choices for managing referable glaucoma exist, easy screening exams are tough to seek out. At current, glaucoma specialists are nonetheless conducting a sequence of advanced investigations utilizing a number of gadgets to identify referable glaucoma.
“Promising outcomes present that our AI can empower healthcare employees and common ophthalmologists to make an goal screening prognosis, particularly at centres missing subtle diagnostic tools,” stated Dr Divya Rao, medical director and head of AI at Remidio.